PHÂN TÍCH CHI PHÍ HIỆU QUẢ CỦA VIỆC BỔ SUNG BUDESONIDE VÀO ĐIỀU TRỊ THÔNG THƯỜNG TRONG ĐIỀU TRỊ ĐỢT CẤP HEN PHẾ QUẢN Ở NGƯỜI BỆNH NHI TẠI VIỆT NAM

Abstract

Objectives: Cost-effectiveness analysis of the addition of budesonide to standard therapy in the treatment of pediatric asthma exacerbation in Vietnam. Research methods: Epidemiology data in Vietnam was used to estimate size of the analysed cohort. A probabilistic Markov cohort model was developed including two main states: severe exacerbation, and discharge. This study was carried out from the payer perspective, with one-week time horizon. Clinical parameters were derived from Razi 2015 trial and costs were extracted from Drug Administration of Vietnam database. Results were expressed as an incremental cost-utility ratio (ICUR), results of one-way sensitivity analysis and probabilistic sensitivity analysis. Results: The addition of budesonide dominated the standard therapy regarding cost-effectiveness. The addition of budesonide was associated with VND 422,734,341 cost savings, quality-adjusted life year (QALY) gains of 2.13 QALYs in the target population. In the probabilistic sensitivity analysis, the addition of budesonide had 99.78% dominant and 0.22% cost-effective (relative to the willingness-to-pay recommended by WHO) compared to usual care. Conclusion: From the payer perspective, the addition of budesonide saved cost while increasing effectiveness relative to the standard therapy in pediatric asthma exacerbation in Vietnam.